ERBB2 and breast neoplasm: This was partially consistent with some recent reports that demonstrated values of peritumoral regions for the assessment of benign and malignant patterns (24), prediction of HER2-enriched (25) and pretreatment evaluation of responses to neoadjuvant chemotherapy (nCRT) (26) in patients with breast tumor.